Results 221 to 230 of about 3,314,611 (329)

Human in vitro neuromuscular junction model to functionally dissect the pathogenic mechanism of anti-AChR autoantibody-positive myasthenia gravis. [PDF]

BMC Pharmacol Toxicol
Shin B, Wang M, Yim J, Kwon E, Magdesian MH, Sayegh CE, Ekert JE, Vadysirisack DD.   +7 more
europepmc   +1 more source

Function, structure and therapeutic potential of complement C5a receptors

British Journal of Pharmacology, 2007
P. Monk, A. Scola, P. Madala, D. Fairlie
semanticscholar   +1 more source

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG‐IgG Dual Seropositive: A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune neuroinflammatory disease, typically characterized by antibodies against aquaporin 4 (AQP4‐IgG) or myelin oligodendrocyte glycoprotein (MOG‐IgG). Simultaneous seropositivity for both antibodies in a single patient is exceedingly rare.
Yeting Luo, Shuhua Xie, Xianghong Liu
wiley   +1 more source

Critical role of complement in antibody mediated rejection in kidney transplantation. [PDF]

World J Transplant
Abbas K, Mubarak M, Musharraf W, Aziz T, Zafar MN.   +4 more
europepmc   +1 more source

Asymmetry of acetylcholinesterase and acetylcholine receptor in intact secretory vesicles from adrenal medulla [PDF]

, 1981
Casey, Chubb, Chubb, Gratzl, Gratzl, Mizobe, Rotundo, Rotundo, Somogyi, Wilson   +9 more
core   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2.

Proceedings of the National Academy of Sciences of the United States of America, 1996
H. Molina, V. Holers, Bin Li, Y. Fung, S. Mariathasan, Joseph J. Goellner, J. Strauss-Schoenberger, R. Karr, D. Chaplin   +8 more
semanticscholar   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Microglia-Mediated Phagocytosis in Alzheimer's Disease: Mechanisms, Heterogeneity, and Therapeutic Insights. [PDF]

Biomolecules
Hassan H, Rawlinson C, Lan YL, Jenkins S, Chen R.   +4 more
europepmc   +1 more source

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source